Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527048 | 1.00 | ENPP2 (0.45) | ENPP2SLC6A4PTGS2KDM1AMAOA | |
| SCHEMBL15212423 | 0.82 | KDM1A (0.60) | KDM1AMAOAMAOB | |
| SCHEMBL18231177 | 0.80 | SLC6A4 (0.44) | ENPP2SLC6A4PTGS2KDM1AMAOA | |
| SCHEMBL21845698 | 0.80 | SLC6A4 (0.44) | ENPP2SLC6A4PTGS2KDM1AMAOA | |
| SCHEMBL21845810 | 0.80 | SLC6A4 (0.44) | ENPP2SLC6A4PTGS2KDM1AMAOA | |
| SCHEMBL15212214 | 0.80 | FFAR1 (0.54) | ENPP2SLC6A4PTGS2KDM1AMAOA | |
| SCHEMBL17795695 | 0.79 | RIPK1 (0.41) | ENPP2SLC6A4PTGS2KDM1AMAOA | |
| SCHEMBL13176976 | 0.74 | PTGS2 (0.51) | ENPP2PTGS2PTGS1 | |
| SCHEMBL2376239 | 0.74 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL8014238 | 0.73 | KMT2A (0.43) | ENPP2SLC6A4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | ENPP2 2518/4885SLC6A4 3413/4885PTGS2 247/4885 |
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | ENPP2 2518/4885SLC6A4 3413/4885PTGS2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.